Frontlight ResearchEarly access
Taking peoplePhase 1
Tests anifrolumab in adults with systemic lupus erythematosus
Tests how safe anifrolumab is and how the body handles it in adults with lupus.
Key facts
- Who runs it
- AstraZeneca AB
- Where
- DO NOT EDIT, HungarySee the siteAlso in 1 other country, 6 sites
- Trial code
- Registry title
- A trial to learn how safe anifrolumab is, how it moves throughout the body over time, and how it affects the body of adults with systemic lupus erythematosus
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 13 people, planned
- Started
- 23 Oct 2026
- Expected to end
- 13 Feb 2031
- Type of study
- Interventional
- Record updated
- 25 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with systemic lupus erythematosus. It studies how safe anifrolumab is and how it moves through the body.
- Age
- 18 years or older
- Sex
- All sexes can join.
Where in Hungary
Also in 1 other country, 6 sites
- Article 11 CTR HUDO NOT EDIT, HungaryNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Plain-language title
- Tests anifrolumab in adults with systemic lupus erythematosusGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 25 September 2026